➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Express Scripts
Boehringer Ingelheim
AstraZeneca
Moodys

Last Updated: September 19, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Bupropion Hydrochloride; Naltrexone Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00129246 ↗ Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 1/Phase 2 2004-12-01 This study will test a combination of the drugs naltrexone and bupropion with weight-concerned smokers to investigate whether or not this combination of drugs improves smoking cessation quit rates and minimizes post quit weight gain.
NCT00129246 ↗ Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain Completed Yale University Phase 1/Phase 2 2004-12-01 This study will test a combination of the drugs naltrexone and bupropion with weight-concerned smokers to investigate whether or not this combination of drugs improves smoking cessation quit rates and minimizes post quit weight gain.
NCT00208169 ↗ Abilify Therapy for Reducing Comorbid Substance Abuse Completed Bristol-Myers Squibb Phase 4 2005-03-01 It is hypothesized that the use of aripiprazole (Abilify) in patients with alcohol and/or drug dependence with comorbid psychiatric conditions will lead to: - Reduction in the amount of alcohol and/or drugs used as measured by the Time Line Follow Back (TLFB) and the Addiction Severity Index (ASI) - Reduction in cravings for alcohol and drugs as measured by the Penn Alcohol Craving Scale - Reduction in symptoms of co-morbid psychiatric disorders compared to before starting aripiprazole.
NCT00208169 ↗ Abilify Therapy for Reducing Comorbid Substance Abuse Completed Creighton University Phase 4 2005-03-01 It is hypothesized that the use of aripiprazole (Abilify) in patients with alcohol and/or drug dependence with comorbid psychiatric conditions will lead to: - Reduction in the amount of alcohol and/or drugs used as measured by the Time Line Follow Back (TLFB) and the Addiction Severity Index (ASI) - Reduction in cravings for alcohol and drugs as measured by the Penn Alcohol Craving Scale - Reduction in symptoms of co-morbid psychiatric disorders compared to before starting aripiprazole.
NCT00364871 ↗ Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity Completed Orexigen Therapeutics, Inc Phase 2 2005-04-01 The purpose of this study is to determine the efficacy and safety of 3 combinations of naltrexone and bupropion SR compared to naltrexone alone, bupropion SR alone or placebo.
NCT00419731 ↗ Study of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation Unknown status National Institute on Drug Abuse (NIDA) Phase 2/Phase 3 2006-11-01 The purpose of this study is to compare the effects of bupropion + placebo to bupropion + naltrexone as treatments to help smokers quit.
NCT00419731 ↗ Study of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation Unknown status University of Minnesota - Clinical and Translational Science Institute Phase 2/Phase 3 2006-11-01 The purpose of this study is to compare the effects of bupropion + placebo to bupropion + naltrexone as treatments to help smokers quit.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Bupropion Hydrochloride; Naltrexone Hydrochloride

Condition Name

Condition Name for Bupropion Hydrochloride; Naltrexone Hydrochloride
Intervention Trials
Obesity 23
Overweight 8
Binge-Eating Disorder 5
Schizophrenia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Bupropion Hydrochloride; Naltrexone Hydrochloride
Intervention Trials
Overweight 15
Obesity 12
Disease 7
Feeding and Eating Disorders 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Bupropion Hydrochloride; Naltrexone Hydrochloride

Trials by Country

Trials by Country for Bupropion Hydrochloride; Naltrexone Hydrochloride
Location Trials
United States 206
Canada 2
Korea, Republic of 1
Greece 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Bupropion Hydrochloride; Naltrexone Hydrochloride
Location Trials
Connecticut 13
California 12
Texas 10
North Carolina 8
Ohio 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Bupropion Hydrochloride; Naltrexone Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Bupropion Hydrochloride; Naltrexone Hydrochloride
Clinical Trial Phase Trials
Phase 4 12
Phase 3 7
Phase 2/Phase 3 8
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Bupropion Hydrochloride; Naltrexone Hydrochloride
Clinical Trial Phase Trials
Completed 18
Not yet recruiting 10
Recruiting 10
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Bupropion Hydrochloride; Naltrexone Hydrochloride

Sponsor Name

Sponsor Name for Bupropion Hydrochloride; Naltrexone Hydrochloride
Sponsor Trials
Orexigen Therapeutics, Inc 15
Yale University 11
National Institute on Drug Abuse (NIDA) 6
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Bupropion Hydrochloride; Naltrexone Hydrochloride
Sponsor Trials
Other 38
Industry 19
NIH 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Baxter
Merck
Colorcon
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.